Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

Contributed by: Business Wire

Logo

Tags

Health

General Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

EADV 2026

More Like This

EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference

Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025

Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis

Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology

Almirall will be celebrating 80 years at the EADV 2024 (Graphic: Almirall)

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis